Trials / Withdrawn
WithdrawnNCT01654081
A Protocol of Irinotecan for Carcinoma of the Lung
A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Susanne Arnold · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this trial is to demonstrate the potential clinical benefit of irinotecan chemotherapy in patients with a specific NSCLC phenotype, ISG15-positive. The use of irinotecan in subjects with ISG15-positive NSCLC will be associated with an improved rate of clinical benefit (objective response, disease stability, and time to progression) compared to historical controls that were not previously selected for ISG-15 expression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan | Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2012-07-31
- Last updated
- 2014-05-30
Source: ClinicalTrials.gov record NCT01654081. Inclusion in this directory is not an endorsement.